Piper Sandler initiated coverage of Bright Minds Biosciences (DRUG) with an Overweight rating and $93 price target The firm believes the company’s lead asset, BMB-101, is a “differentiated” G-protein biased 5-HT2C agonist positioned to drive sustained efficacy in drug-resistant epilepsies with clean safety. Piper sees BMB-101 as a more potent 5-HT2C agonist compared to bexicaserin with no beta-arrestin recruitment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRUG:
- Bright Minds Biosciences initiated with an Overweight at Cantor Fitzgerald
- Bright Minds Biosciences initiated with a Buy at H.C. Wainwright
- Bright Minds Biosciences Appoints New Chief Medical Officer to Advance CNS Therapeutics
- Bright Minds Biosciences appoints Stephen Collins as Chief Medical Officer
- Bright Minds Biosciences (DRUG) Finishes the Year with Phenomenal Share Price Increase